首页 > 最新文献

Asia-Pacific Journal of Ophthalmology最新文献

英文 中文
Diabetic Blindness Remains a Big Challenge Despite All Recent Advancements in Diagnostics and Treatments 尽管诊断和治疗技术不断进步,糖尿病性失明仍然是一个巨大的挑战。
IF 3.7 3区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1016/j.apjo.2024.100105
Jingfa Zhang, Min Wang, Ling Chen, Nishant Radke
{"title":"Diabetic Blindness Remains a Big Challenge Despite All Recent Advancements in Diagnostics and Treatments","authors":"Jingfa Zhang, Min Wang, Ling Chen, Nishant Radke","doi":"10.1016/j.apjo.2024.100105","DOIUrl":"10.1016/j.apjo.2024.100105","url":null,"abstract":"","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"13 5","pages":"Article 100105"},"PeriodicalIF":3.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142370865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
UBM helps differentiate sulcus or in-the-bag IOL placement UBM 帮助区分人工晶体植入是囊内植入还是囊外植入。
IF 3.7 3区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1016/j.apjo.2024.100088
Peng ZhiZhao , Leung Hiu Ying , Nishant Vijay Radke
{"title":"UBM helps differentiate sulcus or in-the-bag IOL placement","authors":"Peng ZhiZhao , Leung Hiu Ying , Nishant Vijay Radke","doi":"10.1016/j.apjo.2024.100088","DOIUrl":"10.1016/j.apjo.2024.100088","url":null,"abstract":"","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"13 5","pages":"Article 100088"},"PeriodicalIF":3.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term Outcomes of Combined Phacotrabeculectomy Surgery in a Singapore Tertiary Hospital 新加坡一家三级医院的咽喉切除联合手术的长期疗效。
IF 3.7 3区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1016/j.apjo.2024.100102
Annabel CY Chew , Hla Myint Htoon , Shamira A. Perera , Tin Aung , Ho Ching Lin , Rahat Husain , Boey Pui Yi , Daniel Hsien Wen Su , Jocelyn Chua , Tina T. Wong

Purpose

To describe the long-term outcomes of phacotrabeculectomy from a tertiary glaucoma service in Singapore.

Design

Retrospective case series.

Methods

Seven hundred ninety-six eyes of 698 patients who underwent phacotrabeculectomy surgery at the Singapore National Eye Centre between 2005 and 2007 with a minimum follow-up of three years were included. The primary outcome measure was intraocular pressure (IOP). Secondary outcomes included best-corrected visual acuity (BCVA), number of glaucoma medications, and surgical complications.

Results

The mean age was 69.5 years, 51 % were male, and 86 % were Chinese. Most eyes had primary glaucoma (90.6 %). The mean follow-up duration was 9.4 years. The overall success rate at three years was 97 % if surgical success was defined as IOP ≤ 21 mm Hg, 92 % if IOP ≤ 18 mm Hg, 66 % if IOP ≤ 15 mm Hg. By Kaplan–Meier survival analysis over 13 years, the cumulative success rate fell from 98.1 % to 89.1 % if IOP ≤ 21 mm Hg, 98.1–76.9 % if IOP ≤ 18 mm Hg, 98–50.3 % if IOP ≤ 15 mm Hg. The postoperative IOP improved significantly at all time points (P < 0.05) and 72 % had at least 20 % IOP reduction. There was a slight improvement in postoperative BCVA (P < 0.05). The mean number of glaucoma medications was reduced postoperatively (P < 0.001). There were no significant risk factors for surgical failure.

Conclusions

Phacotrabeculectomy was found to be safe, resulting in clinically significant IOP lowering for 13 years with reduced dependency on glaucoma medications and improved BCVA.
目的:描述新加坡一家三级青光眼服务机构的虹膜睫状体切除术的长期疗效:设计:回顾性病例系列:方法:纳入 2005 年至 2007 年期间在新加坡国立眼科中心接受青光眼超声乳化手术的 698 名患者中的 796 只眼睛,随访至少三年。主要结果是眼压(IOP)。次要结果包括最佳矫正视力(BCVA)、青光眼用药次数和手术并发症:平均年龄为 69.5 岁,51% 为男性,86% 为中国人。大多数眼睛患有原发性青光眼(90.6%)。平均随访时间为 9.4 年。如果将手术成功定义为眼压≤21毫米汞柱,三年后的总成功率为97%;如果眼压≤18毫米汞柱,总成功率为92%;如果眼压≤15毫米汞柱,总成功率为66%。通过13年的卡普兰-米尔生存分析,如果眼压≤21毫米汞柱,累计成功率从98.1%降至89.1%;如果眼压≤18毫米汞柱,累计成功率从98.1%降至76.9%;如果眼压≤15毫米汞柱,累计成功率从98%降至50.3%。术后眼压在所有时间点均有明显改善(P < 0.05),72%的患者眼压至少降低了 20%。术后 BCVA 略有改善(P < 0.05)。术后青光眼药物的平均数量有所减少(P < 0.001)。手术失败没有明显的风险因素:法氏囊切除术是一种安全的手术,可在13年内显著降低眼压,减少对青光眼药物的依赖,改善BCVA。
{"title":"Long-term Outcomes of Combined Phacotrabeculectomy Surgery in a Singapore Tertiary Hospital","authors":"Annabel CY Chew ,&nbsp;Hla Myint Htoon ,&nbsp;Shamira A. Perera ,&nbsp;Tin Aung ,&nbsp;Ho Ching Lin ,&nbsp;Rahat Husain ,&nbsp;Boey Pui Yi ,&nbsp;Daniel Hsien Wen Su ,&nbsp;Jocelyn Chua ,&nbsp;Tina T. Wong","doi":"10.1016/j.apjo.2024.100102","DOIUrl":"10.1016/j.apjo.2024.100102","url":null,"abstract":"<div><h3>Purpose</h3><div>To describe the long-term outcomes of phacotrabeculectomy from a tertiary glaucoma service in Singapore.</div></div><div><h3>Design</h3><div>Retrospective case series.</div></div><div><h3>Methods</h3><div>Seven hundred ninety-six eyes of 698 patients who underwent phacotrabeculectomy surgery at the Singapore National Eye Centre between 2005 and 2007 with a minimum follow-up of three years were included. The primary outcome measure was intraocular pressure (IOP). Secondary outcomes included best-corrected visual acuity (BCVA), number of glaucoma medications, and surgical complications.</div></div><div><h3>Results</h3><div>The mean age was 69.5 years, 51 % were male, and 86 % were Chinese. Most eyes had primary glaucoma (90.6 %). The mean follow-up duration was 9.4 years. The overall success rate at three years was 97 % if surgical success was defined as IOP ≤ 21 mm Hg, 92 % if IOP ≤ 18 mm Hg, 66 % if IOP ≤ 15 mm Hg. By Kaplan–Meier survival analysis over 13 years, the cumulative success rate fell from 98.1 % to 89.1 % if IOP ≤ 21 mm Hg, 98.1–76.9 % if IOP ≤ 18 mm Hg, 98–50.3 % if IOP ≤ 15 mm Hg. The postoperative IOP improved significantly at all time points (<em>P</em> &lt; 0.05) and 72 % had at least 20 % IOP reduction. There was a slight improvement in postoperative BCVA (<em>P</em> &lt; 0.05). The mean number of glaucoma medications was reduced postoperatively (<em>P</em> &lt; 0.001). There were no significant risk factors for surgical failure.</div></div><div><h3>Conclusions</h3><div>Phacotrabeculectomy was found to be safe, resulting in clinically significant IOP lowering for 13 years with reduced dependency on glaucoma medications and improved BCVA.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"13 5","pages":"Article 100102"},"PeriodicalIF":3.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142340186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bilateral Retinal Detachment Associated with Ascaris suum Infection 与蛔虫感染有关的双侧视网膜脱离
IF 3.7 3区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1016/j.apjo.2024.100100
Tomoyuki Ishibashi, Kazuyuki Emi
{"title":"Bilateral Retinal Detachment Associated with Ascaris suum Infection","authors":"Tomoyuki Ishibashi,&nbsp;Kazuyuki Emi","doi":"10.1016/j.apjo.2024.100100","DOIUrl":"10.1016/j.apjo.2024.100100","url":null,"abstract":"","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"13 5","pages":"Article 100100"},"PeriodicalIF":3.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in understanding and management of IgG4-related ophthalmic disease 对 IgG4 相关眼科疾病的认识和管理进展。
IF 3.7 3区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1016/j.apjo.2024.100101
Kenneth Ka Hei Lai , Terence Wee Xiang Ang , Wah Cheuk , Angie Kwok , Ming Lin , Yael Lustig , Dinesh Selva , Guy Ben Simon , Yue Xing , Zhi Hui Xu , Hua Sheng Yang , Kelvin Kam Lung Chong , Hunter Kwok Lai Yuen
Immunoglobulin G4-related ophthalmic disease (IgG4-ROD) is an emerging, immune-mediated fibroinflammatory orbital disease, characterized by tumefactive lesions with noticeable IgG4+ plasma cell infiltration and distinctive pathohistological features. This disease is often associated with elevated serum IgG4 concentrations. IgG4-ROD may affect any ophthalmic tissues, particularly the lacrimal gland, extraocular muscles, and trigeminal nerves. Although the exact pathogenic role of IgG4 antibodies remains unclear, B-cell depleting agents have been reported to be an effective treatment. The diverse clinical manifestations of IgG4-ROD complicate diagnosis, and without prompt treatment, visual-threatening complications such as optic neuropathy may arise. Recent advances in understanding and managing IgG4-ROD have revolutionized the diagnosis and treatment of this emerging disease. This review article aims to provide a comprehensive overview of the latest advancements in the field of IgG4-ROD.
免疫球蛋白 G4 相关眼科疾病(IgG4-ROD)是一种新出现的免疫介导的眼眶纤维炎性疾病,其特征是具有明显 IgG4+ 浆细胞浸润的肿瘤活性病变和独特的病理组织学特征。这种疾病通常与血清 IgG4 浓度升高有关。IgG4-ROD 可影响任何眼科组织,尤其是泪腺、眼外肌和三叉神经。尽管 IgG4 抗体的确切致病作用尚不清楚,但有报道称 B 细胞去势药物是一种有效的治疗方法。IgG4-ROD 的临床表现多种多样,使诊断变得复杂,如果不及时治疗,可能会出现视神经病变等威胁视力的并发症。近年来,对 IgG4-ROD 的认识和管理取得了进展,为这一新兴疾病的诊断和治疗带来了革命性的变化。这篇综述文章旨在全面概述 IgG4-ROD 领域的最新进展。
{"title":"Advances in understanding and management of IgG4-related ophthalmic disease","authors":"Kenneth Ka Hei Lai ,&nbsp;Terence Wee Xiang Ang ,&nbsp;Wah Cheuk ,&nbsp;Angie Kwok ,&nbsp;Ming Lin ,&nbsp;Yael Lustig ,&nbsp;Dinesh Selva ,&nbsp;Guy Ben Simon ,&nbsp;Yue Xing ,&nbsp;Zhi Hui Xu ,&nbsp;Hua Sheng Yang ,&nbsp;Kelvin Kam Lung Chong ,&nbsp;Hunter Kwok Lai Yuen","doi":"10.1016/j.apjo.2024.100101","DOIUrl":"10.1016/j.apjo.2024.100101","url":null,"abstract":"<div><div>Immunoglobulin G4-related ophthalmic disease (IgG4-ROD) is an emerging, immune-mediated fibroinflammatory orbital disease, characterized by tumefactive lesions with noticeable IgG4+ plasma cell infiltration and distinctive pathohistological features. This disease is often associated with elevated serum IgG4 concentrations. IgG4-ROD may affect any ophthalmic tissues, particularly the lacrimal gland, extraocular muscles, and trigeminal nerves. Although the exact pathogenic role of IgG4 antibodies remains unclear, B-cell depleting agents have been reported to be an effective treatment. The diverse clinical manifestations of IgG4-ROD complicate diagnosis, and without prompt treatment, visual-threatening complications such as optic neuropathy may arise. Recent advances in understanding and managing IgG4-ROD have revolutionized the diagnosis and treatment of this emerging disease. This review article aims to provide a comprehensive overview of the latest advancements in the field of IgG4-ROD.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"13 5","pages":"Article 100101"},"PeriodicalIF":3.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142340185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute Macular Neuroretinopathy Associated with COVID-19 Pandemic: A Real-world Observation Study 与 COVID-19 大流行相关的急性黄斑神经视网膜病变:真实世界观察研究
IF 3.7 3区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1016/j.apjo.2024.100103
Xiaojia Song , Yajie Yu , Haiying Zhou , Yongpeng Zhang , Yu Mao , Hong Wang , Xusheng Cao , Xiaoqing Zhu , Zhihua Li , Lin Li , Jinghua Liu , Xiaoyan Peng , Qian Li

Purpose

To evaluate the clinical and retinal imaging features of Chinese patients with acute macular neuroretinopathy (AMN) associated with COVID-19.

Design

A prospective observational study.

Methods

Retinal imaging, including color fundus photography, near-infrared imaging (NIR), swept-source optical coherence tomography (SS-OCT), optical coherence tomography angiography (OCTA), and Humphrey perimetry, were conducted for each case.

Results

All cases were included within the first three months following the pandemic outbreak. A total of 12 male patients (36.36 %) and 21 female patients (63.64 %) were prospectively recruited, and 29 cases (87.88 %) were bilaterally affected. The median interval between the onset of fever and the appearance of ocular symptoms was two days (range, 0.5–5.0 days). Apart from the outer retinal changes typical of AMN, changes in the inner retinal layers were observed, including intraretinal hemorrhage (8.06 %), cotton wool spots (9.68 %), and paracentral acute middle maculopathy (PAMM) (8.06 %). Smaller retinal inner nuclear layer hyperreflective speckles (RIHS) (41.94 %) were identified as a distinguishing feature from typical PAMM. Voids of vessel signals were found in the superficial (11.54 %), intermediate (82.69 %), and deep capillary plexus (98.08 %), and in the choriocapillaris (19.23 %) on OCTA. Humphrey perimetry illustrated central, paracentral, and peripheral scotomas. The occult lesions associated with AMN, PAMM, and some of the RIHS illustrated by OCT were visualized topographically and further confirmed by OCTA as perfusion defects.

Conclusion

An increase in AMN cases correlated with the SARS-CoV-2 outbreak. Additional features, including widespread inner retinal perfusion deficits, were observed and may serve as potential biomarkers for systemic microcirculation dysregulation in COVID-19.
目的:评估与COVID-19相关的中国急性黄斑神经视网膜病变(AMN)患者的临床和视网膜成像特征:前瞻性观察研究:方法:对每个病例进行视网膜成像,包括彩色眼底照相、近红外成像(NIR)、扫源光学相干断层扫描(SS-OCT)、光学相干断层血管成像(OCTA)和汉弗莱视网膜测量:结果:所有病例都是在大流行爆发后的头三个月内发现的。前瞻性招募了 12 名男性患者(36.36%)和 21 名女性患者(63.64%),29 例患者(87.88%)为双侧受累。从发烧到出现眼部症状的中位间隔为两天(0.5-5.0 天不等)。除了AMN典型的视网膜外层变化外,还观察到视网膜内层的变化,包括视网膜内出血(8.06%)、棉絮斑(9.68%)和旁中心急性中间黄斑病变(PAMM)(8.06%)。较小的视网膜核内层高反射斑点(RIHS)(41.94%)被确定为区别于典型 PAMM 的特征。在 OCTA 上,表层(11.54%)、中间层(82.69%)和深层毛细血管丛(98.08%)以及绒毛膜(19.23%)都发现了血管信号空洞。汉弗莱视网膜测图显示了中心、旁中心和周边视网膜灶。OCT显示的与AMN、PAMM和部分RIHS相关的隐匿性病变可通过地形图观察到,并通过OCTA进一步证实为灌注缺损:结论:AMN病例的增加与SARS-CoV-2爆发有关。结论:AMN病例的增加与SARS-CoV-2疫情有关,同时还观察到其他特征,包括广泛的视网膜内部灌注缺陷,这些特征可能成为COVID-19中全身微循环失调的潜在生物标志物。
{"title":"Acute Macular Neuroretinopathy Associated with COVID-19 Pandemic: A Real-world Observation Study","authors":"Xiaojia Song ,&nbsp;Yajie Yu ,&nbsp;Haiying Zhou ,&nbsp;Yongpeng Zhang ,&nbsp;Yu Mao ,&nbsp;Hong Wang ,&nbsp;Xusheng Cao ,&nbsp;Xiaoqing Zhu ,&nbsp;Zhihua Li ,&nbsp;Lin Li ,&nbsp;Jinghua Liu ,&nbsp;Xiaoyan Peng ,&nbsp;Qian Li","doi":"10.1016/j.apjo.2024.100103","DOIUrl":"10.1016/j.apjo.2024.100103","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the clinical and retinal imaging features of Chinese patients with acute macular neuroretinopathy (AMN) associated with COVID-19.</div></div><div><h3>Design</h3><div>A prospective observational study.</div></div><div><h3>Methods</h3><div>Retinal imaging, including color fundus photography, near-infrared imaging (NIR), swept-source optical coherence tomography (SS-OCT), optical coherence tomography angiography (OCTA), and Humphrey perimetry, were conducted for each case.</div></div><div><h3>Results</h3><div>All cases were included within the first three months following the pandemic outbreak. A total of 12 male patients (36.36 %) and 21 female patients (63.64 %) were prospectively recruited, and 29 cases (87.88 %) were bilaterally affected. The median interval between the onset of fever and the appearance of ocular symptoms was two days (range, 0.5–5.0 days). Apart from the outer retinal changes typical of AMN, changes in the inner retinal layers were observed, including intraretinal hemorrhage (8.06 %), cotton wool spots (9.68 %), and paracentral acute middle maculopathy (PAMM) (8.06 %). Smaller retinal inner nuclear layer hyperreflective speckles (RIHS) (41.94 %) were identified as a distinguishing feature from typical PAMM. Voids of vessel signals were found in the superficial (11.54 %), intermediate (82.69 %), and deep capillary plexus (98.08 %), and in the choriocapillaris (19.23 %) on OCTA. Humphrey perimetry illustrated central, paracentral, and peripheral scotomas. The occult lesions associated with AMN, PAMM, and some of the RIHS illustrated by OCT were visualized topographically and further confirmed by OCTA as perfusion defects.</div></div><div><h3>Conclusion</h3><div>An increase in AMN cases correlated with the SARS-CoV-2 outbreak. Additional features, including widespread inner retinal perfusion deficits, were observed and may serve as potential biomarkers for systemic microcirculation dysregulation in COVID-19.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"13 5","pages":"Article 100103"},"PeriodicalIF":3.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142340184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient Perceptions Regarding the Use of Eyeglasses Among Ophthalmologists 患者对眼科医生使用眼镜的看法。
IF 3.7 3区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1016/j.apjo.2024.100099
Andrew Oh, Brian Chou
{"title":"Patient Perceptions Regarding the Use of Eyeglasses Among Ophthalmologists","authors":"Andrew Oh,&nbsp;Brian Chou","doi":"10.1016/j.apjo.2024.100099","DOIUrl":"10.1016/j.apjo.2024.100099","url":null,"abstract":"","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"13 5","pages":"Article 100099"},"PeriodicalIF":3.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-World Large Sample Assessment of Drug-related Dry Eye Risk: Based on the FDA Adverse Event Reporting System Database 药物相关干眼症风险的真实世界大样本评估:基于 FDA 不良事件报告系统数据库。
IF 3.7 3区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1016/j.apjo.2024.100104
Shi-Nan Wu , Caihong Huang , Yu-Qian Wang , Xiao-Dong Chen , Xiang Li , Si-Qi Zhang , Dan-Yi Qin , Linfangzi Zhu , Chang-Sheng Xu , Qing-He Zhang , Jiaoyue Hu , Zuguo Liu

Purpose and design

This study aimed to evaluate the risk of drug-related dry eye using real-world data, underscoring the significance of tracing pharmacological etiology for distinct clinical types of dry eye.

Methods

Analyzing adverse event reports in the Food and Drug Administration Adverse Event Reporting System (FAERS) from January 2004 to September 2023, we employed disproportionality analysis and the Bayesian confidence propagation neural network algorithm. The analysis involved categorizing drugs causing dry eye, assessing risk levels, and conducting segmental assessments based on the time of onset of drug-related dry eye adverse reactions.

Results

In the FAERS database, adverse reactions related to dry eye were linked to 1160 drugs. Disproportionality analysis identified 33 drugs with significant risk, notably in ophthalmic (brimonidine, bimatoprost), oncology (tisotumab vedotin, erdafitinib), and other medications (isotretinoin, oxymetazoline). The top three drugs with the highest risk of drug-related dry eye are isotretinoin (Bayesian confidence propagation neural network (BCPNN) = 6.88), tisotumab vedotin (BCPNN = 6.88), and brimonidine (BCPNN = 6.77). Among different categories of drugs, respiratory medications have the shortest mean onset time for drug-related dry eye, averaging 50.99 days. The prevalence skewed towards females (69.9 %), particularly in menopausal and elderly individuals (45–70 years old, mean age 54.7 ± 18.2). Reports of drug-related dry eye adverse reactions showed an annual increase.

Conclusion

Informed clinical decision-making is crucial for preventing drug-related dry eye. Assessing the risk of dry eyes associated with both local and systemic medications helps optimize treatment and provide necessary cautionary information.
目的和设计:本研究旨在利用真实世界的数据评估药物相关干眼症的风险,强调对不同临床类型的干眼症进行药理病因追踪的重要性:分析食品药品管理局不良事件报告系统(FAERS)2004 年 1 月至 2023 年 9 月期间的不良事件报告,我们采用了比例失调分析和贝叶斯置信度传播神经网络算法。分析包括对导致干眼症的药物进行分类、评估风险等级,以及根据药物相关干眼症不良反应的发生时间进行分段评估:在 FAERS 数据库中,与干眼症相关的不良反应与 1160 种药物有关。比例失调分析确定了 33 种具有重大风险的药物,尤其是眼科药物(溴莫尼定、比马前列素)、肿瘤药物(替索单抗维多汀、埃达非替尼)和其他药物(异维A酸、奥美沙唑啉)。药物相关干眼症风险最高的前三种药物是异维A酸(贝叶斯置信传播神经网络(BCPNN)=6.88)、替索单抗维多汀(BCPNN=6.88)和溴莫尼丁(BCPNN=6.77)。在各类药物中,呼吸系统药物导致药物性干眼症的平均发病时间最短,平均为 50.99 天。发病率偏向女性(69.9%),尤其是更年期和老年人(45-70 岁,平均年龄为 54.7 ± 18.2)。与药物相关的干眼症不良反应报告呈逐年上升趋势:结论:知情的临床决策对于预防药物相关干眼症至关重要。评估与局部和全身用药相关的干眼症风险有助于优化治疗并提供必要的警示信息。
{"title":"Real-World Large Sample Assessment of Drug-related Dry Eye Risk: Based on the FDA Adverse Event Reporting System Database","authors":"Shi-Nan Wu ,&nbsp;Caihong Huang ,&nbsp;Yu-Qian Wang ,&nbsp;Xiao-Dong Chen ,&nbsp;Xiang Li ,&nbsp;Si-Qi Zhang ,&nbsp;Dan-Yi Qin ,&nbsp;Linfangzi Zhu ,&nbsp;Chang-Sheng Xu ,&nbsp;Qing-He Zhang ,&nbsp;Jiaoyue Hu ,&nbsp;Zuguo Liu","doi":"10.1016/j.apjo.2024.100104","DOIUrl":"10.1016/j.apjo.2024.100104","url":null,"abstract":"<div><h3>Purpose and design</h3><div>This study aimed to evaluate the risk of drug-related dry eye using real-world data, underscoring the significance of tracing pharmacological etiology for distinct clinical types of dry eye.</div></div><div><h3>Methods</h3><div>Analyzing adverse event reports in the Food and Drug Administration Adverse Event Reporting System (FAERS) from January 2004 to September 2023, we employed disproportionality analysis and the Bayesian confidence propagation neural network algorithm. The analysis involved categorizing drugs causing dry eye, assessing risk levels, and conducting segmental assessments based on the time of onset of drug-related dry eye adverse reactions.</div></div><div><h3>Results</h3><div>In the FAERS database, adverse reactions related to dry eye were linked to 1160 drugs. Disproportionality analysis identified 33 drugs with significant risk, notably in ophthalmic (brimonidine, bimatoprost), oncology (tisotumab vedotin, erdafitinib), and other medications (isotretinoin, oxymetazoline). The top three drugs with the highest risk of drug-related dry eye are isotretinoin (Bayesian confidence propagation neural network (BCPNN) = 6.88), tisotumab vedotin (BCPNN = 6.88), and brimonidine (BCPNN = 6.77). Among different categories of drugs, respiratory medications have the shortest mean onset time for drug-related dry eye, averaging 50.99 days. The prevalence skewed towards females (69.9 %), particularly in menopausal and elderly individuals (45–70 years old, mean age 54.7 ± 18.2). Reports of drug-related dry eye adverse reactions showed an annual increase.</div></div><div><h3>Conclusion</h3><div>Informed clinical decision-making is crucial for preventing drug-related dry eye. Assessing the risk of dry eyes associated with both local and systemic medications helps optimize treatment and provide necessary cautionary information.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"13 5","pages":"Article 100104"},"PeriodicalIF":3.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142340187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Accuracy of large language models in answering ophthalmology board-style questions: A meta-analysis 大语言模型在回答眼科委员会类型问题时的准确性:元分析。
IF 3.7 3区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1016/j.apjo.2024.100106
Jo-Hsuan Wu , Takashi Nishida , T. Y. Alvin Liu

Purpose

To evaluate the accuracy of large language models (LLMs) in answering ophthalmology board-style questions.

Design

Meta-analysis.

Methods

Literature search was conducted using PubMed and Embase in March 2024. We included full-length articles and research letters published in English that reported the accuracy of LLMs in answering ophthalmology board-style questions. Data on LLM performance, including the number of questions submitted and correct responses generated, were extracted for each question set from individual studies. Pooled accuracy was calculated using a random-effects model. Subgroup analyses were performed based on the LLMs used and specific ophthalmology topics assessed.

Results

Among the 14 studies retrieved, 13 (93 %) tested LLMs on multiple ophthalmology topics. ChatGPT-3.5, ChatGPT-4, Bard, and Bing Chat were assessed in 12 (86 %), 11 (79 %), 4 (29 %), and 4 (29 %) studies, respectively. The overall pooled accuracy of LLMs was 0.65 (95 % CI: 0.61–0.69). Among the different LLMs, ChatGPT-4 achieved the highest pooled accuracy at 0.74 (95 % CI: 0.73–0.79), while ChatGPT-3.5 recorded the lowest at 0.52 (95 % CI: 0.51–0.54). LLMs performed best in “pathology” (0.78 [95 % CI: 0.70–0.86]) and worst in “fundamentals and principles of ophthalmology” (0.52 [95 % CI: 0.48–0.56]).

Conclusions

The overall accuracy of LLMs in answering ophthalmology board-style questions was acceptable but not exceptional, with ChatGPT-4 and Bing Chat being top-performing models. Performance varied significantly based on specific ophthalmology topics tested. Inconsistent performances are of concern, highlighting the need for future studies to include ophthalmology board-style questions with images to more comprehensively examine the competency of LLMs.
目的:评估大型语言模型(LLM)在回答眼科委员会式问题时的准确性:方法:使用PubMed和Embase在2024年3月进行文献检索:在 2024 年 3 月使用 PubMed 和 Embase 进行文献检索。我们收录了用英文发表的、报道 LLMs 在回答眼科委员会式问题时的准确性的长篇文章和研究报告。我们从单个研究中提取了有关 LLM 表现的数据,包括提交的问题数和生成的正确答案数。采用随机效应模型计算汇总准确率。根据所使用的 LLM 和所涉及的特定眼科主题进行了分组分析:在检索到的 14 项研究中,13 项(93%)针对多个眼科主题测试了 LLM。分别有 12 项(86%)、11 项(79%)、4 项(29%)和 4 项(29%)研究对 ChatGPT-3.5、ChatGPT-4、Bard 和 Bing Chat 进行了评估。LLMs 的总体汇总准确率为 0.65(95% CI:0.61-0.69)。在不同的 LLMs 中,ChatGPT-4 的汇总准确率最高,为 0.74(95% CI:0.73-0.79),而 ChatGPT-3.5 的准确率最低,为 0.52(95% CI:0.51-0.54)。LLM 在 "病理学 "方面的表现最好(0.78 [95% CI:0.70-0.86]),而在 "眼科学基础与原理 "方面的表现最差(0.52 [95% CI:0.48-0.56]):结论:LLMs 在回答眼科委员会式问题时的总体准确性可以接受,但并不出众,ChatGPT-4 和 Bing Chat 是表现最好的模型。根据测试的具体眼科主题,性能差异很大。不一致的表现令人担忧,这凸显了今后的研究需要加入带有图像的眼科板式问题,以更全面地考察 LLM 的能力。
{"title":"Accuracy of large language models in answering ophthalmology board-style questions: A meta-analysis","authors":"Jo-Hsuan Wu ,&nbsp;Takashi Nishida ,&nbsp;T. Y. Alvin Liu","doi":"10.1016/j.apjo.2024.100106","DOIUrl":"10.1016/j.apjo.2024.100106","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the accuracy of large language models (LLMs) in answering ophthalmology board-style questions.</div></div><div><h3>Design</h3><div>Meta-analysis.</div></div><div><h3>Methods</h3><div>Literature search was conducted using PubMed and Embase in March 2024. We included full-length articles and research letters published in English that reported the accuracy of LLMs in answering ophthalmology board-style questions. Data on LLM performance, including the number of questions submitted and correct responses generated, were extracted for each question set from individual studies. Pooled accuracy was calculated using a random-effects model. Subgroup analyses were performed based on the LLMs used and specific ophthalmology topics assessed.</div></div><div><h3>Results</h3><div>Among the 14 studies retrieved, 13 (93 %) tested LLMs on multiple ophthalmology topics. ChatGPT-3.5, ChatGPT-4, Bard, and Bing Chat were assessed in 12 (86 %), 11 (79 %), 4 (29 %), and 4 (29 %) studies, respectively. The overall pooled accuracy of LLMs was 0.65 (95 % CI: 0.61–0.69). Among the different LLMs, ChatGPT-4 achieved the highest pooled accuracy at 0.74 (95 % CI: 0.73–0.79), while ChatGPT-3.5 recorded the lowest at 0.52 (95 % CI: 0.51–0.54). LLMs performed best in “pathology” (0.78 [95 % CI: 0.70–0.86]) and worst in “fundamentals and principles of ophthalmology” (0.52 [95 % CI: 0.48–0.56]).</div></div><div><h3>Conclusions</h3><div>The overall accuracy of LLMs in answering ophthalmology board-style questions was acceptable but not exceptional, with ChatGPT-4 and Bing Chat being top-performing models. Performance varied significantly based on specific ophthalmology topics tested. Inconsistent performances are of concern, highlighting the need for future studies to include ophthalmology board-style questions with images to more comprehensively examine the competency of LLMs.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"13 5","pages":"Article 100106"},"PeriodicalIF":3.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142387538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current research and future strategies for the management of vision-threatening diabetic retinopathy 治疗危及视力的糖尿病视网膜病变的当前研究和未来策略。
IF 3.7 3区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-09-01 DOI: 10.1016/j.apjo.2024.100109
Huating Li , Weiping Jia , Stela Vujosevic , Charumathi Sabanayagam , Jakob Grauslund , Sobha Sivaprasad , Tien Yin Wong
Diabetic retinopathy (DR) is a major ocular complication of diabetes and the leading cause of blindness and visual impairment, particularly among adults of working-age adults. Although the medical and economic burden of DR is significant and its global prevalence is expected to increase, particularly in low- and middle-income countries, a large portion of vision loss caused by DR remains preventable through early detection and timely intervention. This perspective reviewed the latest developments in research and innovation in three areas, first novel biomarkers (including advanced imaging modalities, serum biomarkers, and artificial intelligence technology) to predict the incidence and progression of DR, second, screening and early detection of referable DR and vision-threatening DR (VTDR), and finally, novel therapeutic strategies for VTDR, including diabetic macular oedema (DME), with the goal of reducing diabetic blindness.
糖尿病视网膜病变(DR)是糖尿病的主要眼部并发症,也是导致失明和视力损伤的主要原因,尤其是在工作年龄的成年人中。尽管糖尿病视网膜病变造成了巨大的医疗和经济负担,而且预计其全球发病率还会增加,尤其是在中低收入国家,但通过早期发现和及时干预,糖尿病视网膜病变造成的大部分视力损失仍然是可以预防的。本视角回顾了三个领域研究和创新的最新进展,首先是新型生物标志物(包括先进的成像模式、血清生物标志物和人工智能技术),用于预测DR的发病率和进展情况;其次是可转诊DR和视力威胁性DR(VTDR)的筛查和早期检测;最后是VTDR(包括糖尿病黄斑水肿(DME))的新型治疗策略,目的是减少糖尿病性失明。
{"title":"Current research and future strategies for the management of vision-threatening diabetic retinopathy","authors":"Huating Li ,&nbsp;Weiping Jia ,&nbsp;Stela Vujosevic ,&nbsp;Charumathi Sabanayagam ,&nbsp;Jakob Grauslund ,&nbsp;Sobha Sivaprasad ,&nbsp;Tien Yin Wong","doi":"10.1016/j.apjo.2024.100109","DOIUrl":"10.1016/j.apjo.2024.100109","url":null,"abstract":"<div><div>Diabetic retinopathy (DR) is a major ocular complication of diabetes and the leading cause of blindness and visual impairment, particularly among adults of working-age adults. Although the medical and economic burden of DR is significant and its global prevalence is expected to increase, particularly in low- and middle-income countries, a large portion of vision loss caused by DR remains preventable through early detection and timely intervention. This perspective reviewed the latest developments in research and innovation in three areas, first novel biomarkers (including advanced imaging modalities, serum biomarkers, and artificial intelligence technology) to predict the incidence and progression of DR, second, screening and early detection of referable DR and vision-threatening DR (VTDR), and finally, novel therapeutic strategies for VTDR, including diabetic macular oedema (DME), with the goal of reducing diabetic blindness.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"13 5","pages":"Article 100109"},"PeriodicalIF":3.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Asia-Pacific Journal of Ophthalmology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1